Regimen Improved Survival in Children With High-Risk Wilms Tumors

Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

In this video, Dr. Dix, discusses the results of two phase III trials that showed that in children with high-risk Wilms tumor, treatment with vincristine and dactinomycin plus the addition of doxorubicin improved outcomes.

In this video, Dr. Dix, of the British Columbia Children’s Hospital in Vancouver, discusses results of two phase III Children’s Oncology Group clinical trials that found that in children with high-risk Wilms tumor, treatment with vincristine and dactinomycin plus the addition of doxorubicin improved outcomes. The data were presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting. Read our conference report on this study.

Related Videos
Increasing age, higher Gleason scores, and higher pathologic stages are predictors of mortality in patients with prostate cancer, according to an expert from Dana-Farber Cancer Institute.
Clinical trials highlight benefits, including radiographic progression-free survival following treatment with radioligand 177Lu-PSMA-617 in pretreated patients with metastatic castration-resistant prostate cancer.
Early data from ongoing clinical trials suggest the potential safety and efficacy of novel radium-223 combinations as treatment for metastatic castration-resistant prostate cancer.
An expert from Dana-Farber Cancer Institute discusses findings from the final overall survival analysis of the phase 3 ENGOT-OV16/NOVA trial.
The use of palliative care in ovarian cancer resulted in a decrease in overall readmissions and index hospitalization costs.
Current clinical trials look to assess 177Lu-PSMA-617 in combination with other therapies including androgen deprivation therapy and docetaxel.
An expert from Dana-Farber Cancer Institute indicates that patients with prostate cancer who have 1 risk factor should undergo salvage radiotherapy following radical prostatectomy before their prostate-specific antigen level rises above 0.25 ng/ml.
An expert from Weill Cornell Medicine highlights key clinical data indicating the benefits of radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer.
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Related Content

RUBY Trial Supports Addition of Dostarlimab to Chemo as SOC in Endometrial Cancer

March 28th 2023

Using Germline Testing to Inform Treatment Decisions in Breast Cancer

May 29th 2019

Botensilimab Plus Balstilimab Yields Enduring Responses in R/R Ovarian Cancer

March 28th 2023

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

May 29th 2019

Adavosertib Yields Clinical Activity in Uterine Serous Carcinoma

March 28th 2023

Durvalumab Combo Appears Tolerable in Gynecologic Cancers

March 28th 2023

RUBY Trial Supports Addition of Dostarlimab to Chemo as SOC in Endometrial Cancer

March 28th 2023

Using Germline Testing to Inform Treatment Decisions in Breast Cancer

May 29th 2019

Botensilimab Plus Balstilimab Yields Enduring Responses in R/R Ovarian Cancer

March 28th 2023

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

May 29th 2019

Adavosertib Yields Clinical Activity in Uterine Serous Carcinoma

March 28th 2023

Durvalumab Combo Appears Tolerable in Gynecologic Cancers

March 28th 2023

RUBY Trial Supports Addition of Dostarlimab to Chemo as SOC in Endometrial Cancer

March 28th 2023

Using Germline Testing to Inform Treatment Decisions in Breast Cancer

May 29th 2019

Botensilimab Plus Balstilimab Yields Enduring Responses in R/R Ovarian Cancer

March 28th 2023

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

May 29th 2019

Adavosertib Yields Clinical Activity in Uterine Serous Carcinoma

March 28th 2023

Durvalumab Combo Appears Tolerable in Gynecologic Cancers

March 28th 2023